Patient P-01365

Synthetic patientNBL-101 · Day 109 · 25–34 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 50 SC-12 recommended — Supportive Compound SC-12
Day 51 Patient accepted — Started SC-12 in the companion
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 57 GI symptom burden −23% vs expected — Supportive Compound SC-12
Day 63 No meaningful change — GI Support Protocol GI-04
Day 63 Tolerance state changed — Unstable → Improving
Day 64 ME-01 recommended — Monitoring Escalation ME-01
Day 65 Patient accepted — Started ME-01 in the companion
Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days

GI instability-23
Nutritional resilience+12
Inflammatory activity-10
Treatment adherence-5

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Supportive Compound SC-12Day 50
Result: symptom burden −23%
GI Support Protocol GI-04Day 54
Result: no meaningful change
Monitoring Escalation ME-01Day 64
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Clinician Review CR-01

72%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

43.8/100

stable · -0.2 vs previous 14 d

Toxicity

Blood

42/100

stable · -0.1 vs previous 14 d

Sleep quality

Wearable

30.4/100

stable · +0.1 vs previous 14 d

Energy level

Daily log

4/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

5.9/10

stable · -0.1 vs previous 14 d

Steps

Wearable

3,294

improving · +473 vs previous 14 d

Adherence

Companion

45.8 %

stable · +1.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 39 from the failing basin, 48 from restoration.

Would help

CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 60%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
NP-02 Dietary Support Protocol
already tried, no meaningful change
Keep fat low
GI +4.9 next day on high-intake days · n 22
Keep histamine low
GI +4.3 next day on high-intake days · n 20
Keep simple carbs low
GI +3.4 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.9detractor · 95%
Histamine load
+4.3detractor · 95%
Simple carbohydrates
+3.4detractor · 95%
Alcohol
+3.2detractor · 68%
Spicy / capsaicin
-1.6no signal · 36%
Insoluble fibre
+1.4no signal · 32%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓40
- DNAFUT2 non-secretor lowers mucosal fucosylation
- WearableSleep 5.9 h, below personal baseline
Autonomic recovery ↑40
- Wearable3,294 steps/day
- WearableShort sleep window
Inflammatory signalling ↓25
- BloodInflammatory load index 50
Drug metabolism and exposure ↑20
- BloodToxicity index 42

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Rapid metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.5 · butyrate capacity 44/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 37 ms
Sleep: 5.4 h
Steps: 2,210
Resting HR: 67 bpm

Daily log: GI score 44, nutritional resilience 48, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01473	60%	S14	GI-04	improved	51
P-01556	60%	S14	GI-04	improved	44
P-01486	57%	S18	GI-04	improved	47
P-01570	56%	S14	SC-12	improved	46
P-01389	55%	S14	SC-12	improved	46
P-01438	55%	S14	GI-04	improved	56
P-01566	54%	S09	GI-04	improved	52
P-01356	53%	S14	GI-04	improved	42
P-01458	53%	S14	GI-04	improved	44
P-01543	53%	S14	GI-04	improved	54
P-01603	53%	S14	GI-04	improved	40
P-01339	52%	S14	GI-04	improved	54